Key result
Oncology-specific equations (Oncpeak) and HF-FRIEND accurately estimated Vo2peak in breast cancer survivors, with 86% and 81% of estimates within ±3.5 mL O2·kg−1·min−1 of measured values.
Why the study?
Estimated Vo2peak is widely used in oncology, but existing equations were developed in noncancer settings.
Do estimated Vo2peak equations accurately reflect directly measured Vo2peak in women previously treated for primary breast cancer?
Observational (n=380)
Do estimated Vo2peak equations accurately reflect directly measured Vo2peak in women previously treated for primary breast cancer?
HF-FRIEND and newly developed oncology-specific equations accurately estimate Vo2peak in women previously treated for breast cancer, providing a valid alternative when cardiopulmonary exercise testing is unavailable.
May support VO2peak estimation with Oncpeak or HF-FRIEND in breast cancer survivors; leaves open prospective validation in broader cohorts.
Estimated peak oxygen consumption (Vo2peak) is widely used in oncology; however, estimated Vo2peak equations were developed in noncancer settings. The aim of this study was to evaluate the validity of estimated Vo2peak in women with primary breast cancer and to develop oncology-specific estimated Vo2peak equations. Vo2peak was directly measured (TrueOne 2400, Parvo Medics) during 380 cardiopulmonary exercise tests in women previously treated for breast cancer (mean age: 59 ± 10 years; 3.1 ± 1.2 years post-therapy). The American College of Sports Medicine (ACSM), the Fitness Registry and the Importance of Exercise National Database (FRIEND), and heart failure (HF)-FRIEND equations were used to estimate Vo2peak. New equations were developed using patient and peak (Oncpeak) or submaximal (Oncsub) exercise test characteristics. The median differences between measured and estimated Vo2peak were 7.0 mL O2·kg−1·min−1, 3.9 mL O2·kg−1·min−1, and −0.2 mL O2·kg−1·min−1 for ACSM, FRIEND, and HF-FRIEND, respectively. The number of estimated Vo2peak values within ±3.5 mL O2·kg−1·min−1 of the measured values was 70 (18%), 164 (43%), and 306 (81%) for ACSM, FRIEND, and HF-FRIEND, respectively. The Oncpeak and OncSub models included body mass index, age, a history of chemotherapy or radiation, the peak measured heart rate, and the treadmill grade and/or speed. The median differences between measured and estimated Vo2peak were 0.02 mL O2·kg−1·min−1 (Oncpeak) and −0.2 mL O2·kg−1·min−1 (Oncsub). Eighty-six percent (n = 325) and 76% (n = 283) estimated Vo2peak values were within ±3.5 mL O2·kg−1·min−1 of the measured Vo2peak values for Oncpeak and Oncsub, respectively. HF-FRIEND or oncology-specific equations could be applied to estimate Vo2peak in patients previously treated for breast cancer in settings where cardiopulmonary exercise tests are not available. (Trial Comparing the Effects of Linear Versus Nonlinear Aerobic Training in Women With Operable Breast Cancer [EXCITE]; NCT01186367
No takes yet. Share an insight, caveat, or question.
Michalski et al. (2022) conducted an observational in Primary breast cancer (n=380). Estimated Vo2peak equations (Oncpeak, Oncsub, HF-FRIEND) vs. Directly measured Vo2peak was evaluated on Median difference between measured and estimated Vo2peak. Oncology-specific equations (Oncpeak) and HF-FRIEND accurately estimated Vo2peak in breast cancer survivors, with 86% and 81% of estimates within ±3.5 mL O2·kg−1·min−1 of measured values.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: